Skip to main content
Premium Trial:

Request an Annual Quote

Lab21 to Offer Saladax Chemotherapy Management Tests

NEW YORK (GenomeWeb News) – Saladax Biomedical today said that Lab21 will offer the firm's Personalized Chemotherapy Management assays as a service offering in the UK, Ireland, and Middle East, under a distribution agreement between the firms.

Bethlehem, Pa.-based Saladax said that Lab21 is the first clinical reference lab to offer testing services based on the firm's 5-fluorouracil PCM reagent kits. Cambridge, UK-based Lab21 will market the dose-management service under the trade name DoseCheck.

Berwyn Clarke, chief scientific and development officer for Lab21, said in a statement that the test "will provide higher physician confidence in dosing this widely used drug and will provide patients with the potential of longer survival with a better quality of life while undergoing treatment."

Filed under

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.